Heptares Therapeutics Limited

Nxera Pharma UK Limited

Other

Mark Pickworth

Miles Stuart Congreve

Giles Albert Brown

Benjamin Gerald Tehan

Santosh Shripad Kulkarni

Julie Elaine Cansfield

Barry John Teobald

John Andrew Christopher

Jonathan Stephen Mason

Sarah Joanne Bucknell

Francesca Deflorian

Mark David Rackham

Michael Alistair O'Brien

Charlotte Fieldhouse

Nigel Alan Swain

Michael Alistair O'brien

Giovanni Bottegoni

Chris De Graaf

Barry John Teobold

Julie Cansfield

Paul Mcgee

Alicia Perez Higueruelo

Pyrazole derivatives as H4 antagonist compounds

This invention related to compounds having activity as muscarinic Mor Mand Mreceptor agonists which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where X; X; X; X; Y; Z; n, Rand Rare defined herein.

Quinolinone and benzoxazine derivatives as muscarinic Mand/or Mreceptor agonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor and which are useful in the treatment of muscarinic Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X, X, R, R, Rand Rare as defined herein.

Muscarinic receptor agonists

The disclosures herein relate to novel compounds of formula

CGRP receptor antagonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor and/or Mreceptor and which are useful in the treatment of muscarinic M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R, R, R, Rand Rare as defined herein.

Muscarinic agonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor or Mand Mreceptors and which are useful in the treatment of muscarinic Mor M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q, Q, R, p, V, Q, Q, X, Xand W are defined herein.

Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor and/or Mreceptor and which are useful in the treatment of muscarinic M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1a or a salt thereof, wherein n, p, Q, R, R, R, Rand Rare as defined herein.

This invention relates to compounds that are agonists of the muscarinic Mreceptor and/or Mreceptor and which are useful in the treatment of muscarinic M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R, R', R, Rand Rare as defined herein.

This invention relates to compounds that are agonists of the muscarinic Mreceptor and/or Mreceptor and which are useful in the treatment of muscarinic M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula (1) or a salt thereof, wherein p, q, r, s, Q, Rand Rare as defined herein.

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R, R, Rand Rare as defined herein. 

Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor

The disclosures herein relate to novel compounds of formula wherein R, R, Rand Rare as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Substituted spirocyclohexanes as muscarinic Mreceptor and/or Mreceptor agonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor and/or M4 receptor and which are useful in the treatment of muscarinic M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R, R, R, Rand Rare as defined herein. 

Growing community of inventors

Welwyn Garden City, United Kingdom

Mark Pickworth